pilsicainide has been researched along with Chronic Disease in 4 studies
pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pilsicainide is a newly synthesized antiarrhythmic agent with class Ic properties." | 6.69 | Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study. ( Aonuma, K; Azegami, K; Igawa, M; Nishizaki, M; Okishige, K; Yamawaki, N, 2000) |
| "Pilsicainide is a newly synthesized antiarrhythmic agent with class Ic properties." | 2.69 | Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study. ( Aonuma, K; Azegami, K; Igawa, M; Nishizaki, M; Okishige, K; Yamawaki, N, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Watanabe, I | 1 |
| Okumura, Y | 1 |
| Ohkubo, K | 1 |
| Nagashima, K | 1 |
| Sonoda, K | 1 |
| Mano, H | 1 |
| Kofune, M | 1 |
| Hirayama, A | 1 |
| Takada, Y | 1 |
| Isobe, S | 1 |
| Okada, M | 1 |
| Ando, A | 1 |
| Nonokawa, M | 1 |
| Inden, Y | 1 |
| Tomita, Y | 1 |
| Suzuki, A | 1 |
| Hirai, M | 1 |
| Murohara, T | 1 |
| Okishige, K | 1 |
| Nishizaki, M | 1 |
| Azegami, K | 1 |
| Igawa, M | 1 |
| Yamawaki, N | 1 |
| Aonuma, K | 1 |
| Sato, T | 1 |
| Mitamura, H | 1 |
| Kurita, Y | 1 |
| Takeshita, A | 1 |
| Shinagawa, K | 1 |
| Miyoshi, S | 1 |
| Kanki, H | 1 |
| Hara, M | 1 |
| Ogawa, S | 1 |
2 trials available for pilsicainide and Chronic Disease
| Article | Year |
|---|---|
Effects of antiarrhythmic agents on left ventricular function during exercise in patients with chronic left ventricular dysfunction.
Topics: Aged; Anti-Asthmatic Agents; Chronic Disease; Disopyramide; Exercise; Exercise Test; Female; Heart V | 2004 |
Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Drug Admin | 2000 |
2 other studies available for pilsicainide and Chronic Disease
| Article | Year |
|---|---|
Pharmacologic atrial defibrillation by drug delivery into the temporarily occluded coronary sinus. A canine study.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Balloon Occlusion; Cardiac Pacing, Artificial; | 2012 |
Electropharmacologic effects of pilsicainide, a pure sodium channel blocker, on the remodeled atrium subjected to chronic rapid pacing.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; C | 2001 |